atezolizumab,vinorelbine
roche
['ipsos', 'atezo']
#esmo22 #ipsos with a median f/u of 41 mo, atezolizumab monotherapy resulted in significantly improved os (mos: 10.3 vs 9.3 mo; hr-0.78; p=.028). the improved was seen across subgroups and independent of pd-l1 expression 
CME experts Sara Fagerlie, PhD, CHCP & Mindy Tanzola, PhD have joined forces at Front Row to help clinicians & educators manage the oncology information deluge